Adjuvant Capital

Adjuvant Capital is a private life sciences investment firm focused on global health rather than a drug-developing biopharma company. The firm invests in companies developing drugs, vaccines, diagnostics, medical devices, and related health technologies aimed at high-burden and neglected public health challenges, particularly in low- and middle-income countries. Its stated focus areas include infectious diseases, antimicrobial resistance, maternal and child health, reproductive and sexual health, and nutrition. Adjuvant emphasizes opportunities with human proof-of-concept, typically seeking technologies with Phase 2-or-later efficacy signals or similar external validation. The firm operates as an impact-oriented investor seeking both financial returns and measurable public health impact.